Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review

被引：0
|
作者：
Ann M. Murray
Jennifer I. Stern
Carrie E. Robertson
Chia-Chun Chiang
机构：
[1] Mayo Clinic,Department of Neurology
来源：
Current Pain and Headache Reports | 2022年 / 26卷
关键词：
Real-world studies; CGRP; Monoclonal antibody; CGRP receptor antagonist; Medication overuse; Chronic migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：783 / 794
页数：11
相关论文
共 50 条
  • [31] A REAL-WORLD STUDY OF THE PATIENT EXPERIENCE WITH ABALOPARATIDE
    Gold, D. T.
    Weiss, R. J.
    Roberts, J.
    Bailey, T.
    Wang, Y.
    James, A.
    Mohseni, M.
    Williams, S.
    VALUE IN HEALTH, 2020, 23 : S231 - S231
  • [32] Abaloparatide Real-World Patient Experience Study
    Gold, Deborah T.
    Weiss, Richard
    Beckett, Tammy
    Deal, Chad
    Epstein, Robert S.
    James, Andrew L.
    Kernaghan, Jacqueline M.
    Mohseni, Mahshid
    Spiegel, Michael
    Vokes, Tamara
    Roberts, Jenna
    Bailey, Tom
    Wang, Yamei
    Williams, Setareh A.
    JBMR PLUS, 2021, 5 (03)
  • [33] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 48 - 49
  • [34] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey
    TOXICON, 2022, 214 : S39 - S40
  • [35] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey Manack
    FRONTIERS IN NEUROLOGY, 2022, 12
  • [36] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine
    Mechtler, L. L.
    Saikali, N. P.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    HEADACHE, 2021, 61 : 176 - 177
  • [37] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 74 - 74
  • [38] Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review
    Fernandez-Guarino, Montserrat
    Ortiz, Pablo
    Gallardo, Fernando
    Llamas-Velasco, Mar
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
  • [39] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review
    Salim, Amira
    Hennessy, Elise
    Sonneborn, Claire
    Hogue, Olivia
    Biswas, Sudipa
    Mays, Maryann
    Suneja, Aarushi
    Ahmed, Zubair
    Mata, Ignacio F.
    CNS DRUGS, 2024, 38 (06) : 481 - 491
  • [40] Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
    Vandenbussche, Nicolas
    Pisarek, Karolina
    Paemeleire, Koen
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
12345